SearchDictionaryMobileLogin

Inflammation

68720  relevant articles (2485 outcomes, 6304 trials/studies) found for this Disease

Description: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.

Also Known As:
Inflammations

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pain (Aches)
2. Asthma (Bronchial Asthma)
3. Infection
4. Fibrosis (Cirrhosis)
5. Neoplasms (Cancer)

Experts

1. Serhan, Charles N: 17 articles (08/2008 - 01/2002)
2. Gelfand, Erwin W: 16 articles (04/2008 - 07/2002)
3. Cuzzocrea, Salvatore: 15 articles (02/2008 - 01/2002)
4. Lindholm, Bengt: 14 articles (09/2008 - 01/2002)
5. Yoshikawa, Toshikazu: 14 articles (08/2008 - 07/2002)
6. Yanagisawa, Rie: 14 articles (05/2008 - 01/2002)
7. Thiemermann, Christoph: 14 articles (02/2008 - 01/2002)
8. Takano, Hirohisa: 14 articles (11/2006 - 01/2002)
9. Jilma, Bernd: 13 articles (02/2008 - 05/2002)
10. Schiffrin, Ernesto L: 12 articles (08/2008 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Inflammation:
1. Adrenal Cortex Hormones (Corticosteroids)IBA
2. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
3. CytokinesIBA
4. AntigensIBA
5. Interleukin-10 (Interleukin 10)IBA
6. Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
7. CarrageenanIBA
8. Interleukin-6 (Interleukin 6)IBA
9. Dexamethasone (Maxidex)FDA LinkGeneric
10. Biological Markers (Surrogate Marker)IBA

Therapies and Procedures

1. Transplants (Transplant)
2. Aftercare (After-Treatment)
3. Immunotherapy
4. Lasers (Laser)
5. Transplantation (Transplant Recipients)
04/01/2008 - "Interestingly, whereas three-time application of MSC-CM was partially effective, transplantation of MSC achieved a better outcome in suppressing corneal inflammation"
05/01/2000 - "CONCLUSIONS: Amniotic membrane transplantation is effective in promoting re-epithelialization and reducing inflammation, thus preventing scarring sequelae in the late stage"
03/01/2008 - "In the present study, we were able to visualize intestinal GVHD-associated inflammation in an allogeneic murine transplantation model by (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in vivo"
08/01/2007 - "This may be attributed to the discrepancies in the methods of detection, study subject selection (early or late post transplantation), presence of inflammation, and false identification of infiltrating leukocytes"
09/01/2005 - "The effects in clinical studies of UDCA on the endpoints "death" or "pre-transplantation survival" can only be shown when UDCA therapy is started in an early disease phase, preferably in stage I but no later than stage II, and is then continued into stages III/IV, or preferably stage IV. The reasons for this lie in the observation that, in stages I/II, no patient suffers from progressive disease that irrevocably leads to death or transplantation, while a measurable effect of UDCA, as is true for other drugs and other hepatic diseases, continues to dwindle and finally disappears as patients progress through the fibrotic and cirrhotic stages III and IV. Hence, administration of UDCA must begin in the phase of progressive inflammation (stages I and II) and the outcome documented after many years of long-term therapy"
Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Inflammation

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 2485 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>